Today, the FDA approved Novartis’ drug Cosentyx (secukinumab), which is used to treat adults with moderate to severe plaque psoriasis, a skin disease caused by problems with the immune system.   Cosentryx is an injectable treatment, and is the first drug to be approved to block the IL-17 protein, which plays a role in inflammation.  Some analysts believe the drug has blockbuster potential.Knoxville Institute of Dermatology in Knoxville will continue to keep you updated on this exciting and promising new treatment for psoriasis, a condition which affects 3% of the population.Read more about Cosentyx here!types_psoriases1Dr. Quyn Rahman